top of page

Biopharma Daily Stock Updates - 02/01/22

$XBI $94.94 | +1.62%


Covid Updates

$PFE +0.7% & $BNTX +4.4% Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request from U.S. FDA source

Pipeline Updates

$BCRX -0.8% BioCryst to Present New ORLADEYO® (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting. source

$DNLI +3.3% Denali Therapeutics Announces Presentations on DNL310 (ETV:IDS) Development Program in MPS II (Hunter Syndrome) at the Upcoming WORLDSymposium™. source

$JAGX +3.4% Jaguar Health Announces Completion of Third-party, Investigator-Initiated Study of Crofelemer, which is Expected to Support Orphan Drug Designation (ODD) for Crofelemer for Congenital Diarrheal Disorders (CDD). source

$VERU +6.4% Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio® in Phase 3 ENABLAR-2 Trial. source

$SLS +3.9% SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer. source

$ALDX +1.4% Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model. source

$ARQT +2.6% Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis. source

$CYTK +1.1% Cytokinetics Announces Positive Topline Results from Cohort 3 of REDWOOD-HCM. source

$EGRX +0.1% Eagle Pharmaceuticals Announces Commercial Availability of PEMFEXY™. source

$SQZ -1.6% SQZ Biotechnologies Announces Publication of Comprehensive Preclinical Research on SQZ® APC’s Ability to Overcome Fundamental Biological Barrier to Effective and Efficient Killer T Cell Activation. source

$MNOV +5.0% MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Korea. source

$LVTX +6.2% LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer. source

$GLSI +12.1% Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01. source

$IBRX +4.6% ImmunityBio Announces Promising Clinical Study Results for ‘Kick and Kill’ HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy. source

$SIOX -23.1% Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis, Extension of Cash Runway, and CEO Transition. source

Business Updates

$SRNE +0.3% Sorrento Completes Acquisition of Virex Health, Will Commercialize Next-Generation at-Home Diagnostic Testing That Rivals PCR-Level Sensitivity for Daily Covid-19 Tests and Early Cancer Diagnosis. source

$CRTX +12.3% Cortexyme Announces Pipeline Update and Anticipated 2022 Milestones. source

$SRPT +3.7% Sarepta Therapeutics and GenEdit Share Progress on Research Collaboration and Announce Agreement to Develop Gene Editing Therapeutics for Neuromuscular Diseases. source


Posted by FS/JM

bottom of page